PA8564001A1 - Aza-arilpiperazinas - Google Patents
Aza-arilpiperazinasInfo
- Publication number
- PA8564001A1 PA8564001A1 PA20038564001A PA8564001A PA8564001A1 PA 8564001 A1 PA8564001 A1 PA 8564001A1 PA 20038564001 A PA20038564001 A PA 20038564001A PA 8564001 A PA8564001 A PA 8564001A PA 8564001 A1 PA8564001 A1 PA 8564001A1
- Authority
- PA
- Panama
- Prior art keywords
- disorders
- nervous system
- central nervous
- arilpiperazinas
- aza
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A COMPUESTOS QUIMICOS DE LA FORMULA (I) ASI, COMO A SALES, SOLVATOS Y ESTERES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, EN LA QUE DE R1 A R4 TIENEN LOS SIGNIFICADOS DEFINIDOS EN LA REIVINDICACION 1. PUEDEN UTILIZARSE EN FORMA DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO O PREVENCION DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL, LESIONES DEL SISTEMA NERVIOSO CENTRAL, TRASTORNOS CARDIOVASCULARES, TRASTORNOS GASTROINTESTINALES, DIABETES, OBESIDAD Y APNEA NOCTURNA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0202015.4A GB0202015D0 (en) | 2002-01-29 | 2002-01-29 | Piperazine Derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8564001A1 true PA8564001A1 (es) | 2003-09-05 |
Family
ID=9929954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20038564001A PA8564001A1 (es) | 2002-01-29 | 2003-01-28 | Aza-arilpiperazinas |
Country Status (33)
Country | Link |
---|---|
US (1) | US7098337B2 (es) |
EP (1) | EP1472255B1 (es) |
JP (1) | JP4213042B2 (es) |
KR (1) | KR100644004B1 (es) |
CN (1) | CN1290847C (es) |
AR (1) | AR038237A1 (es) |
AT (1) | ATE318817T1 (es) |
AU (1) | AU2003205622B2 (es) |
BR (1) | BR0307291A (es) |
CA (1) | CA2472954C (es) |
DE (1) | DE60303791T2 (es) |
DK (1) | DK1472255T3 (es) |
EA (1) | EA200400881A1 (es) |
EC (1) | ECSP045208A (es) |
ES (1) | ES2259757T3 (es) |
GB (1) | GB0202015D0 (es) |
GT (1) | GT200300015A (es) |
HR (1) | HRP20040653A2 (es) |
IL (1) | IL162727A0 (es) |
MA (1) | MA27097A1 (es) |
MX (1) | MXPA04007147A (es) |
NO (1) | NO20043547L (es) |
PA (1) | PA8564001A1 (es) |
PE (1) | PE20030847A1 (es) |
PL (1) | PL371922A1 (es) |
PT (1) | PT1472255E (es) |
RS (1) | RS65704A (es) |
SI (1) | SI1472255T1 (es) |
TN (1) | TNSN04136A1 (es) |
TW (1) | TW200307683A (es) |
UY (1) | UY27627A1 (es) |
WO (1) | WO2003064423A1 (es) |
ZA (1) | ZA200405458B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA84146C2 (ru) * | 2003-05-21 | 2008-09-25 | Прозидион Лимитед | Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний |
US7405210B2 (en) | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
GB0314967D0 (en) | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
TW200528102A (en) * | 2003-10-24 | 2005-09-01 | Solvay Pharm Gmbh | Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
RU2006117637A (ru) * | 2003-10-24 | 2007-12-10 | Зольвай Фармасьютиклз Гмбх (De) | Комбинированное лечение ожирения с применением избирательных антагонистов cb1-рецептора и ингибиторов липаз |
EP1792629A4 (en) | 2004-08-25 | 2010-08-25 | Takeda Pharmaceutical | PREVENTIVE / REMEDY AGENTS FOR INCONTINENCE OF STRESS AND SELECETING METHOD THEREOF |
MX2007004889A (es) | 2004-10-25 | 2007-09-11 | Solvay Pharm Gmbh | Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados. |
ATE514698T1 (de) | 2005-05-03 | 2011-07-15 | Hoffmann La Roche | Tetracyclische azapyrazinoindoline als 5-ht2- liganden |
WO2006125179A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
RU2417226C2 (ru) * | 2005-11-18 | 2011-04-27 | Ф.Хоффманн-Ля Рош Аг | Производные азаиндол-2-карбоксамида |
ATE448230T1 (de) | 2005-12-09 | 2009-11-15 | Hoffmann La Roche | Für die behandlung von obesitas geeignete tricyclische amidderivate |
KR101015666B1 (ko) | 2005-12-16 | 2011-02-22 | 에프. 호프만-라 로슈 아게 | H3 수용체 조절제로서 피롤로[2,3-b]피리딘 유도체 |
EP2018863B9 (en) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
US20100266504A1 (en) | 2007-11-15 | 2010-10-21 | Takahiro Matsumoto | Condensed pyridine derivative and use thereof |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
CN104302620A (zh) * | 2012-04-26 | 2015-01-21 | 弗朗西斯·泽维尔·塔瓦雷斯 | 内酰胺的合成 |
TWI506027B (zh) * | 2012-08-06 | 2015-11-01 | Hoffmann La Roche | 哌并[1,2-a]吲哚-1-酮及[1,4]二氮呯并[1,2-a]吲哚-1-酮 |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
JPWO2019131902A1 (ja) | 2017-12-27 | 2020-12-10 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
DK1105122T3 (da) | 1998-08-14 | 2005-08-08 | Hoffmann La Roche | Pharmaceutical compositions containing lipase inhibitors |
ES2217797T3 (es) | 1998-08-14 | 2004-11-01 | F. Hoffmann-La Roche Ag | Vinileteres heterociclicos contra trastornos neurologicos. |
GB9902047D0 (en) * | 1999-01-29 | 1999-03-17 | Cerebrus Ltd | Chemical compounds XI |
FR2799757B1 (fr) * | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2002
- 2002-01-29 GB GBGB0202015.4A patent/GB0202015D0/en not_active Ceased
-
2003
- 2003-01-17 KR KR1020047011619A patent/KR100644004B1/ko not_active IP Right Cessation
- 2003-01-17 JP JP2003564046A patent/JP4213042B2/ja not_active Expired - Fee Related
- 2003-01-17 ES ES03702462T patent/ES2259757T3/es not_active Expired - Lifetime
- 2003-01-17 CA CA002472954A patent/CA2472954C/en not_active Expired - Fee Related
- 2003-01-17 SI SI200330231T patent/SI1472255T1/sl unknown
- 2003-01-17 BR BR0307291-6A patent/BR0307291A/pt not_active IP Right Cessation
- 2003-01-17 AT AT03702462T patent/ATE318817T1/de active
- 2003-01-17 WO PCT/EP2003/000459 patent/WO2003064423A1/en active IP Right Grant
- 2003-01-17 AU AU2003205622A patent/AU2003205622B2/en not_active Ceased
- 2003-01-17 MX MXPA04007147A patent/MXPA04007147A/es unknown
- 2003-01-17 DE DE60303791T patent/DE60303791T2/de not_active Expired - Lifetime
- 2003-01-17 EA EA200400881A patent/EA200400881A1/ru unknown
- 2003-01-17 EP EP03702462A patent/EP1472255B1/en not_active Expired - Lifetime
- 2003-01-17 CN CNB03802943XA patent/CN1290847C/zh not_active Expired - Fee Related
- 2003-01-17 RS YU65704A patent/RS65704A/sr unknown
- 2003-01-17 IL IL16272703A patent/IL162727A0/xx unknown
- 2003-01-17 PT PT03702462T patent/PT1472255E/pt unknown
- 2003-01-17 DK DK03702462T patent/DK1472255T3/da active
- 2003-01-17 PL PL03371922A patent/PL371922A1/xx not_active Application Discontinuation
- 2003-01-24 US US10/350,616 patent/US7098337B2/en not_active Expired - Fee Related
- 2003-01-24 PE PE2003000073A patent/PE20030847A1/es not_active Application Discontinuation
- 2003-01-27 AR ARP030100229A patent/AR038237A1/es unknown
- 2003-01-27 GT GT200300015A patent/GT200300015A/es unknown
- 2003-01-28 PA PA20038564001A patent/PA8564001A1/es unknown
- 2003-01-28 TW TW092101825A patent/TW200307683A/zh unknown
- 2003-01-28 UY UY27627A patent/UY27627A1/es not_active Application Discontinuation
-
2004
- 2004-06-30 MA MA27756A patent/MA27097A1/fr unknown
- 2004-07-08 ZA ZA200405458A patent/ZA200405458B/en unknown
- 2004-07-16 HR HR20040653A patent/HRP20040653A2/hr not_active Application Discontinuation
- 2004-07-22 TN TNP2004000136A patent/TNSN04136A1/en unknown
- 2004-07-27 EC EC2004005208A patent/ECSP045208A/es unknown
- 2004-08-25 NO NO20043547A patent/NO20043547L/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8564001A1 (es) | Aza-arilpiperazinas | |
PA8523601A1 (es) | Derivados de piperazina | |
PA8534801A1 (es) | Derivados de piperazina | |
AR058163A1 (es) | Medicamentos exhaltadores del deseo sexual que comprenden derivados de benzimidazolona | |
UY27204A1 (es) | Derivados de pieracina | |
TW200716208A (en) | Modified and immediate release memantine bead formulation | |
HN2005000255A (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
ECSP077401A (es) | Medicamentos que contienen compuestos de carbonilo y su uso | |
CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
GT200100183A (es) | Derivados de quinolina y quinazolina. | |
IS2517B (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki | |
HN2002000275A (es) | Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados | |
UY28752A1 (es) | Agentes terapeuticos | |
UY27300A1 (es) | Nuevos derivados de quinolina | |
WO2007100366A3 (en) | Quinolone m1 receptor positive allosteric modulators | |
UY28923A1 (es) | Compuestos terapéuticos: piridina como estructura base | |
AR021893A1 (es) | Compuesto de 2-fenil-1-(3,4-dihidroxi-5-nitrofenil)-1-etanona sustituida , su uso para la manufactura de un medicamento en el tratamiento de algunos trastornos del sistema nervioso central y periférico y composiciones farmacéuticas que las contienen | |
ECSP088283A (es) | Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
UY27646A1 (es) | Derivados de quinolina como antagonistas de npt | |
ATE543491T1 (de) | Kombinationspräparat enthaltend ibuprofen und paracetamol | |
CL2008001820A1 (es) | Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer. | |
UY28839A1 (es) | Agentes terapeuticos | |
BRPI0407097A (pt) | Antagonista do casr | |
GEP20094854B (en) | Compounds for treating diseases of impaired gastric motility | |
UY29741A1 (es) | Sales de 1,5- diaril pirazol-3-carboxamidas, procesos de preparación, composeciones farmacéuticas que las contienen, aplicaciones y métodos de uso. |